Obagi Launches ELASTIderm, a Significant Advance in Eye Skincare.

LONG BEACH, Calif. -- Obagi Medical Products, Inc. (NASDAQ:OMPI) today announced the introduction of ELASTIderm[TM] Eye Cream, a novel eye-therapy product clinically proven to help the natural abilities of skin to produce insoluble elastin, decrease the number of wrinkles and increase functional elasticity of the skin. Although most cosmetic treatment products to date utilize moisturizing ingredients to help reduce the appearance of lines around the eyes, ELASTIderm utilizes a patent-pending bi-mineral complex technology with malonic acid to offer a superior approach to anti-aging treatment without the use of line-plumping moisturizers.

"We are excited to have developed such an efficacious technology in the treatment of periorbital wrinkles. We feel this product has tremendous potential to create new demand in the dynamic category of doctor-dispensed skincare," said Steven Carlson, President and CEO of Obagi Medial Products.

"ELASTIderm uses Obagi's exclusive Penetrating Therapeutics, an effective patent-pending technology that allows for greater penetration of an active agent across the skin barrier to stimulate functional elasticity and to enhance the resilience of the skin around the eyes," stated Carlson. "Recent clinical studies on ELASTIderm demonstrated a statistically significant 46% increase in functional elasticity after nine weeks of use, reinforcing Obagi Medical Products as the leader in elastin science."

Formulated with a novel, bi-mineral complex that works to replenish and cross link elastin to support collagen and give skin functional elasticity, the scientific data revealed the patent-pending complex was effective in improving the elasticity of photoaged skin and visibly reducing periorbital lines. A significant increase in elasticity was achieved within only two weeks and elasticity continued to increase over an eight-week period. Importantly, the increase in elasticity was independent of moisturization, indicating the effects of the bi-mineral complex were not simply the consequence of increased hydration.

Obagi ELASTIderm Eye Cream is available only in dermatologists', plastic surgeons', and skin-care oriented physicians' offices nationwide.

About Obagi Medical Products, Inc.

Obagi, a leader in the physician-dispensed skin care channel, develops and commercializes skin health products for the dermatology, plastic surgery, and related Aesthetic markets. Using its Penetrating Therapeutics[TM] technologies, Obagi's products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin such as chloasma, melasma, senile lentigines, acne vulgaris and sun damage. Obagi launched its first skincare system, Obagi Nu-Derm[TM], in 1988 and in 2004 launched the first and only prescription strength Vitamin C and hydroquinone system, Obagi-C Rx[TM]. Obagi System products are only available through physicians. Visit www.obagi.com for information.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should," "potential," "anticipates," "plans" or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances and the possibility that our products may cause undesirable side effects. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Registration Statement on Form S-1. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.